ES2288305T3 - Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso. - Google Patents

Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso. Download PDF

Info

Publication number
ES2288305T3
ES2288305T3 ES97940941T ES97940941T ES2288305T3 ES 2288305 T3 ES2288305 T3 ES 2288305T3 ES 97940941 T ES97940941 T ES 97940941T ES 97940941 T ES97940941 T ES 97940941T ES 2288305 T3 ES2288305 T3 ES 2288305T3
Authority
ES
Spain
Prior art keywords
cxcr3
protein
antibody
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97940941T
Other languages
English (en)
Spanish (es)
Inventor
Marcel Loetscher
Bernhard Moser
Shixin Qin
Charles R. Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kocher Theodor Institut
THEODOR-KOCHER INSTITUTE
Millennium Pharmaceuticals Inc
Original Assignee
THEODOR-KOCHER INSTITUTE
Kocher Theodor Institut
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27108320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2288305(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/709,838 external-priority patent/US6140064A/en
Application filed by THEODOR-KOCHER INSTITUTE, Kocher Theodor Institut, Millennium Pharmaceuticals Inc filed Critical THEODOR-KOCHER INSTITUTE
Application granted granted Critical
Publication of ES2288305T3 publication Critical patent/ES2288305T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES97940941T 1996-09-10 1997-09-10 Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso. Expired - Lifetime ES2288305T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US709838 1996-09-10
US08/709,838 US6140064A (en) 1996-09-10 1996-09-10 Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US08/829,839 US6184358B1 (en) 1996-09-10 1997-03-31 IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
US829839 1997-03-31

Publications (1)

Publication Number Publication Date
ES2288305T3 true ES2288305T3 (es) 2008-01-01

Family

ID=27108320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97940941T Expired - Lifetime ES2288305T3 (es) 1996-09-10 1997-09-10 Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.

Country Status (8)

Country Link
EP (1) EP0925358B1 (enExample)
JP (1) JP4502408B2 (enExample)
AT (1) ATE360689T1 (enExample)
AU (1) AU734090B2 (enExample)
CA (1) CA2265915C (enExample)
DE (1) DE69737656T2 (enExample)
ES (1) ES2288305T3 (enExample)
WO (1) WO1998011218A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
SE9801098D0 (sv) * 1998-03-30 1998-03-30 Astra Pharma Prod Receptors
AU3962099A (en) * 1998-05-07 1999-11-23 William Douglas Mckee Valve assembly
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response
EP1127126B1 (en) * 1998-11-06 2006-10-18 Bayer HealthCare AG G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
DE60031418T2 (de) 1999-08-03 2007-08-23 Millennium Pharmaceuticals, Inc., Cambridge 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
MXPA02005199A (es) * 1999-11-24 2002-11-07 Schering Corp Metodos para inhibir metastasis.
AU2001249546A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Methods for treating disease with antibodies to cxcr3
EP1987842A1 (en) 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitor
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP1411966A4 (en) * 2001-07-12 2005-06-01 Univ California METHOD FOR TREATING SECONDARY TISSUE ENERGY IN CONNECTION WITH DAMAGE TO THE CENTRAL NERVOUS SYSTEM
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
EP1491209A4 (en) * 2002-02-28 2006-05-17 Kyowa Hakko Kogyo Kk MEANS FOR DIAGNOSIS AND TREATMENT OF INTERSTITIAL PNEUMONIA
WO2003082335A1 (fr) * 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Co., Ltd. Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe
EP2402310A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
EP2256116A3 (en) 2002-11-18 2011-11-16 ChemoCentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
JP4870357B2 (ja) 2002-12-20 2012-02-08 ケモセントリックス， インコーポレイテッド ヒト腫瘍発現ｃｃｘｃｋｒ２の阻害剤
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7405275B2 (en) * 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CA2606222C (en) 2005-04-21 2015-06-23 Chemocentryx, Inc. Reagents that bind ccx-ckr2
WO2007105224A1 (en) 2006-03-16 2007-09-20 Protagonists Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
CN101796073B (zh) * 2007-02-01 2014-08-13 特瓦生物制药美国有限公司 针对cxcr3的人源化抗体
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
KR101617050B1 (ko) 2007-07-12 2016-05-02 케모센트릭스, 인크. 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
EP2804878B1 (en) * 2012-01-20 2018-08-22 Genzyme Corporation Anti-cxcr3 antibodies
WO2014003742A1 (en) * 2012-06-27 2014-01-03 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
WO2014008385A1 (en) 2012-07-05 2014-01-09 Cornell University Compositions and methods useful for making orthotopic tumors with controllable metastasis
WO2014186842A1 (en) * 2013-05-22 2014-11-27 Monash University Antibodies and uses thereof
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20240066061A1 (en) * 2021-01-12 2024-02-29 Charité-Universitätsmedizin Berlin A cxcr3+ cell or cell preparation for use in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69031914T2 (de) * 1989-08-11 1998-07-30 Amrad Corp. Ltd., Kew, Victoria Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
DK0669979T3 (da) * 1992-11-10 2006-03-06 Genentech Inc C-C CKR-1, kemokinreceptor
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor

Also Published As

Publication number Publication date
CA2265915A1 (en) 1998-03-19
EP0925358B1 (en) 2007-04-25
DE69737656D1 (de) 2007-06-06
AU4260897A (en) 1998-04-02
WO1998011218A1 (en) 1998-03-19
CA2265915C (en) 2012-11-20
JP4502408B2 (ja) 2010-07-14
JP2002513388A (ja) 2002-05-08
DE69737656T2 (de) 2008-01-03
ATE360689T1 (de) 2007-05-15
AU734090B2 (en) 2001-06-07
EP0925358A1 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
ES2288305T3 (es) Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
US6184358B1 (en) IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
JP4398620B2 (ja) ヒト化抗ｃｃｒ−２抗体およびその使用方法
ES2335948T3 (es) Anticuerpos anti-ccr2 y metodos de uso de los mismos.
US6537764B1 (en) Method of identifying inhibitors of C—C chemokine receptor 3
US6528625B1 (en) Anti-CCR5 antibodies and kits comprising same
US6806061B1 (en) G protein-coupled receptor gene and methods of use therefor
WO1996022371A9 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
AU2005202131B2 (en) CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
AU779916B2 (en) CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
AU727636B2 (en) C-C chemokine receptor 3: CKR-3 or Eos-L2
AU2800001A (en) C-C chemokine receptor 3:CKR-3 or Eos-L2
AU3709601A (en) G protein-coupled receptor antagonists